Title氨柔比星对治疗一线含铂化疗后复发患者的意义:一项多中心Ⅱ期临床研究的结果
Other TitlesPhase Ⅱ Study of Amrubicin as Second-Line Therapy in Patients with Platinum-Refractory Small-Cell Lung Cancer
Authors王洁
陈志勇
Affiliation北京大学肿瘤医院,北京,100036
广东省人民医院肿瘤中心、广东省医学科学院、广东省肺癌研究所,广州,510080
Keywords小细胞肺癌
复发
氨柔比星
Issue Date2012
Publisher循证医学
Citation循证医学.2012,12,(1),38-40.
Abstract1 文献来源 Ettinger DS,Jotte R,Lorigan P,ct al.Phase Ⅱ study of Amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer[J].J Clin Oncol,2010,28(15):2598-2603.2证据水平lb.3背景小细胞肺癌占肺癌的15%,在确诊的时候已有60%~70%处于广泛期.尽管小细胞肺癌初治患者对化疗药物较敏感,但很快产生耐药性并复发,且复发患者的预后很差.
URIhttp://hdl.handle.net/20.500.11897/31821
ISSN1671-5144
DOI10.3969/j.issn.1671-5144.2012.01.008
Indexed中国科技核心期刊(ISTIC)
中国科学引文数据库(CSCD)
Appears in Collections:北京肿瘤医院

Web of Science®



Checked on Last Week

Scopus®



Checked on Current Time

百度学术™



Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.